These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 16572113)
1. Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Alaupovic P; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Samuelsson O Kidney Int; 2006 May; 69(10):1865-71. PubMed ID: 16572113 [TBL] [Abstract][Full Text] [Related]
2. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104 [TBL] [Abstract][Full Text] [Related]
3. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group. Dallongeville J; Fruchart JC; Pfister P; Bard JM J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein-B subclasses as acceptors of cholesteryl esters transferred by CETP. Lee DM; Alaupovic P; Knight-Gibson C; Bagdade JD Eur J Clin Invest; 2008 Oct; 38(10):734-42. PubMed ID: 18761668 [TBL] [Abstract][Full Text] [Related]
5. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group. Dallongeville J; Fruchart JC; Pfister P; Bard JM Am J Med; 1994 Jun; 96(6A):32S-36S. PubMed ID: 8017464 [TBL] [Abstract][Full Text] [Related]
6. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802 [TBL] [Abstract][Full Text] [Related]
7. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Lintott CJ; Scott RS; Bremer JM; Shand BI Am J Cardiol; 1995 Jul; 76(2):97A-101A. PubMed ID: 7604809 [TBL] [Abstract][Full Text] [Related]
8. Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Hilpert KF; West SG; Kris-Etherton PM; Hecker KD; Simpson NM; Alaupovic P Am J Clin Nutr; 2007 Feb; 85(2):369-76. PubMed ID: 17284731 [TBL] [Abstract][Full Text] [Related]
9. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Alaupovic P; Mack WJ; Knight-Gibson C; Hodis HN Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):715-22. PubMed ID: 9108785 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333 [TBL] [Abstract][Full Text] [Related]
11. LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans. Bagdade JD; Jilma B; Hudgins LC; Alaupovic P; McCurdy CE Lipids Health Dis; 2018 May; 17(1):127. PubMed ID: 29807532 [TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease. Knowlton N; Wages JA; Centola MB; Alaupovic P Scand J Rheumatol; 2012 May; 41(3):165-9. PubMed ID: 22401593 [TBL] [Abstract][Full Text] [Related]
13. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Lye M; Valacio R; Reckless JP; Ghosh AK; Findlay IN; Ghosh MK; Passmore AP; Fulcher RA Coron Artery Dis; 1998; 9(9):583-90. PubMed ID: 9861520 [TBL] [Abstract][Full Text] [Related]
14. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. März W; Scharnagl H; Abletshauser C; Hoffmann MM; Berg A; Keul J; Wieland H; Baumstark MW Circulation; 2001 Apr; 103(15):1942-8. PubMed ID: 11306521 [TBL] [Abstract][Full Text] [Related]
15. CETP-mediated cholesteryl ester enrichment of apoB subclasses in type 1 diabetes. Bagdade JD; Knight-Gibson C; Simpson N; Gerkin R; Alaupovic P; Reardon C Eur J Clin Invest; 2012 Jul; 42(7):709-16. PubMed ID: 22288873 [TBL] [Abstract][Full Text] [Related]
16. Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. Skulas-Ray AC; Alaupovic P; Kris-Etherton PM; West SG J Clin Lipidol; 2015; 9(3):360-7. PubMed ID: 26073395 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786 [TBL] [Abstract][Full Text] [Related]
18. Acute effects of interleukin-6 infusion on apo-B-containing lipoprotein subclasses in humans. Bagdade J; Pedersen BK; Schwenke D; Saremi A; Alaupovic P Scand J Clin Lab Invest; 2011 Oct; 71(6):449-55. PubMed ID: 21923231 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis. Knowlton N; Wages JA; Centola MB; Giles J; Bathon J; Quiroga C; Alaupovic P Arthritis Care Res (Hoboken); 2012 Jul; 64(7):993-1000. PubMed ID: 22337612 [TBL] [Abstract][Full Text] [Related]
20. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Alaupovic P Curr Atheroscler Rep; 2003 Nov; 5(6):459-67. PubMed ID: 14525679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]